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infections (UTIs) occurring within 1 month after TR-PB. 
The rate of symptomatic UTIs and the rate of ADRs were 
considered the main outcome measures.
Results In the total study population, 72/1109 (6.5 %) 
patients experienced symptomatic UTIs and among these 
11 (0.9 % of total) had urosepsis. Out of 72, 53 (73.6 %) 
symptomatic UTIs were caused by fluoroquinolone-resist-
ant strains. Out of 632, 10 (1.6 %) patients in Group 1 
and 62/477 (12.9 %) patients in Group 2 had symptomatic 
UTIs (p < 0.001); in particular, 2/632 (0.3 %) patients in 
Group 1 and 9/477 (1.8 %) patients in Group 2 had urosep-
sis (p < 0.001). No differences were reported in terms of 
adverse events (0.6 vs 0.4 %; p = 0.70). A Charlson comor-
bidity index ≤1 and type of antimicrobial prophylaxis (FT) 
were found to be associated with a lower probability of 
symptomatic UTIs in the multivariate model.
Conclusions Antibiotic prophylaxis with FT for TR-PB 
had a lower rate of adverse events and a lower rate of 
symptomatic UTIs as compared with CIP. Fosfomycin tro-
metamol appears as an attractive alternative prophylactic 
regimen in prostate biopsies.
Keywords Prostate biopsy · Fosfomycin trometamol · 
Fluoroquinolone · Prophylaxis · Transrectal 
ultrasonography · Urinary tract infection
Introduction
Prostate biopsy is currently an indispensable method 
for the diagnosis of prostate cancer, and the transrectal 
approach is most commonly used by European urologists 
[1–3]. Even if transrectal biopsy of the prostate (TR-PB) 
is generally considered a safe method, it may be accom-
panied by severe clinical complications, ranging from 
Abstract 
Objective To compare fosfomycin trometamol (FT) and 
ciprofloxacin (CIP) for antibiotic prophylaxis in transrectal 
prostate biopsy (TR-PB).
Patients and methods Data for 1109 patients (mean age 
66.7 ± 8.45) who underwent TR-PB between March to 
September 2015 in seven Italian urological institutions 
were retrospectively reviewed, of which 632 received FT 
(Group 1) and 477 received CIP (Group 2) for prophy-
laxis. We reviewed all urine culture results obtained after 
the procedure, all adverse drug reactions (ADRs) related 
to the drug and all febrile and/or symptomatic urinary tract 
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bleeding due to the biopsy trauma to infectious compli-
cations including asymptomatic bacteriuria, symptomatic 
urinary tract infections (UTIs) and sepsis [4]. In recent 
years, a higher rate of infectious complications after 
TR-PB has been reported [5]. The rate is correlated with 
increasing antimicrobial resistance, especially to fluoro-
quinolones which are the current first-line recommended 
antibiotics. In fact, a dramatic increase in ciprofloxacin-
resistant strains among Escherichia coli with decreasing 
efficacy of ciprofloxacin prophylaxis in patients under-
going TR-PB has been reported [6]. The current rate of 
fluoroquinolone-resistant organisms has become a sig-
nificant health problem [3]. The situation is due both to 
over-prescription of antibiotics and the limited number 
of available, especially oral antibiotics for prophylaxis in 
TR-PB. Furthermore, there are no new antibiotics in the 
pipelines of the pharmaceutical companies to replace oral 
fluoroquinolones in the near future [3, 7]. Thus, infectious 
complications after TR-PB represent an important chal-
lenge for the urologist and for patients. On the other hand, 
several authors reported that fosfomycin trometamol (FT) 
could be a valid alternative for antibiotic prophylaxis of 
TR-PB due to its low profile of resistance, elevated activity 
against multidrug-resistant (MDR) Gram-negative bacteria 
and favorable pharmacokinetic properties [8–10]. Here, 
we aimed to compare the clinical outcome of patients who 
underwent TR-PB and received prophylaxis with either FT 
or ciprofloxacin (CIP), by means of a retrospective, com-
parative cohort study.
Patients and methods
Study design and population
Our study population consisted of a cohort of patients who 
underwent TR-PB in 7 tertiary referral urological institu-
tions from January to September 2015. Each trialist was 
asked to select all consecutive patients who had received 
antibiotic prophylaxis for prostate biopsy with FT or CIP 
during the 9-month study period. Clinical and microbiolog-
ical data were collected by reviewing all electronic medi-
cal charts and, if needed, by reviewing medical ward charts 
or by calling the patients. All collected patients were dived 
into two groups. Group 1: patients who received a dose of 
3 g FT orally 3 h before and 3 g 24 h after the first admin-
istration (in line with the registration recommendations); 
Group 2: all patients who received 500 mg CIP as proph-
ylaxis administered orally twice daily for 5 days starting 
1 day before the procedure.
In Group 2, we decided to collect data only from 
patients who had undergone CIP prophylaxis for the fol-
lowing reasons:
•	 CIP is the most common antibiotic prescribed in Italy 
for TR-PB prophylaxis.
•	 We wanted to obtain a group of patients as homogenous 
as possible for comparison and further analysis.
Rate of symptomatic UTIs was the primary end point. 
All clinical and microbiological data were compared 
between the two groups. Adverse drug reactions (ADRs) 
were the secondary end points and were registered accord-
ing to the Clavien–Dindo classification [11].
Ethical considerations
The present study has a retrospective cohort design. The 
medical records of groups of individuals who are alike in 
many ways but differ by a certain characteristic (patients 
receiving antibiotic prophylaxis with FT versus CIP) are 
compared for a particular outcome (rate of symptomatic 
UTIs) [12]. The study was conducted in line with the 
STROBE statement (http://www.strobe-statement.org). 
Figure 1 shows the study flowchart. Due to the retrospec-
tive nature and due to the fact that FT has been registered 
in Italy for diagnostic urological procedures, the study did 
not require approval by the local ethics committee (IRB). 
All anamnestic, clinical and laboratory data containing 
protected patient’s health information were de-identified 
in order to use anonymous data for analysis. The de-iden-
tification was performed by non-medical staff by means of 
dedicated software. Trialists did not process or analyze data 
until after the de-identification process.
Inclusion and exclusion criteria
We included all patients older than 18 years and candidates 
for prostate biopsy, in line with the indications of the Euro-
pean Association of Urology (EAU) [13]. Subjects affected 
by significant comorbidities (Charlson comorbidity 
index >3) [14] and with known anatomical abnormalities of 
the urinary tract were excluded from the study. In order to 
obtain as homogenous cohorts of patients as possible, the 
microbiological history of all patients was evaluated and all 
patients who reported previous symptomatic UTIs due to 
fluoroquinolone-resistant and fosfomycin-resistant strains 
were excluded.
Biopsy procedure
Before TR-PB, all patients in this retrospective analysis 
underwent the following procedure: dipstick urinalysis 
(leukocyte esterase test and nitrite test) and/or micro-
scopic urinalysis and urine culture. A urine culture taken 
before the procedure was mandatory for inclusion. All 
patients received a self-administered fleet enema (sodium 
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phosphate and dibasic sodium phosphate) 2 h before the 
biopsy. At the procedure time, the microbiological results 
were reviewed and all patients with a positive urine cul-
ture were excluded if not treated before. In patients who 
had been treated before, a negative microbiological control 
after therapy was required before biopsy. With the patient 
in the left-lying position, the urologist performed transrec-
tal ultrasound with a multiplanar multifrequency probe 
attached to the ultrasound scanner. Before prostate biopsy, 
local anesthesia was administered transrectally. Prostate 
biopsies (12 cores) were taken using an automated biopsy 
gun with a disposable 16 gauge x 25 cm biopsy needle. 
All intra-procedural complications were recorded, and all 
patients were instructed to return to the emergency depart-
ment of the same hospital if they developed complications 
such as fever, chills, macroscopic hematuria or severe void-
ing symptoms. A follow-up visit for discussing histological 
results of the prostate biopsy and for evaluation of possible 
complications was scheduled 30 days after the procedure. 
Only patients who also had a urine culture at the follow-up 
visit were included.
Data collection and microbiological considerations
The following data were recorded retrospectively: age, 
Charlson comorbidity index, microbiological results of 
a midstream-voided urine before TR-PB, date of TR-PB, 
patient-related and external risk factors for UTI develop-
ment, PSA level, results of the digital rectal examination, 
IPSS and IIEF-5 questionnaires before the procedure (as 
it is routine in each urological institution), the presence 
of adverse events related to the antibiotics or to the proce-
dure, Clavien–Dindo complication score, microbiological 
results of a midstream-voided urine after TR-PB and histo-
logical findings. We registered all episodes of symptomatic 
UTIs that occurred within 1 month after the procedure. A 
1-month interval was chosen to increase the likelihood of 
capturing all symptomatic UTIs attributable to the prostate 
biopsy [15]. Data were collected by reviewing all ambu-
latory and hospital medical charts in case of hospitaliza-
tion for symptomatic UTIs. In line with EAU guidelines, 
we defined an episode of symptomatic UTI as follows 
[16–18]:
•	 body temperature <38 °C and dysuria accompanied by 
pyuria.
•	 Fever ≥38 °C accompanied by one symptom of the 
lower urinary tract (i.e., urgency, frequency, dysuria, or 
suprapubic tenderness).
•	 Fever ≥38 °C, accompanied by chills and malaise
•	 urosepsis as defined in the EAU guidelines on urologi-
cal infections [18].
Fig. 1  The study flow chart
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The classification of peri-procedural complications was 
performed using the Clavien–Dindo classification [11]. 
Although symptomatic UTIs confirmed by microbiologi-
cal analysis were the main outcome parameter in this study, 
all other symptoms were also recorded and considered. All 
bacterial isolates were identified by standard microbiologi-
cal methods according to Hooton et al. [19], and suscep-
tibility testing was performed according to CLSI (Clini-
cal and Laboratory Standards Institute) recommendations. 
All MIC values of isolates were interpreted according to 
the breakpoints of European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) [20]. All institutions fol-
lowed these criteria. For microbiological diagnosis of UTI, 
a cutoff of ≥105 colony-forming units/mL were used in all 
institutions.
Questionnaires
The validated Italian versions of the International Pros-
tate Symptom Score (IPSS) [21] and International Index 
of Erectile Function (IIEF) [22] were administered to each 
patient, as it is routine in each urological institution. The 
questionnaire was offered to the patient on arrival at each 
center before the procedure and at the first follow-up visit 
after the procedure.
Safety
The safety of the antibiotics was assessed in terms of fre-
quency and nature of ADRs. The association between 
ADRs and drug treatment was performed in agreement 
with Gallelli et al. [23] by means of the Naranjo Adverse 
Probability Scale [24]. Records positive for ADRs were 
reviewed by blinded clinicians, who simply looked for 
reported ADRs in clinical records and completed the 
Naranjo probability scale.
Statistical analysis
The Fisher’s exact test or a two-tailed t test or Mann–Whit-
ney test was used to assess the statistical significance as 
appropriate. For the purpose of the case–control com-
parison between patients included in the two groups, all 
cases of symptomatic UTIs were matched on the basis of 
this criterion: similar age (age difference not exceeding 
±5 years). All results have been adjusted by all risk fac-
tors for biopsy-related UTI complications, such as number 
of previous biopsy series. Continuous variables were given 
as the mean ± standard deviation. Relative risks and 95 % 
confidence intervals were estimated by applying log-bino-
mial regression and Cox regression with a constant in the 
time variable. The following co-variables have been used in 
the multivariate analysis: previous UTIs (yes/no), Charlson 
comorbidity index (0/1/2), smoking (yes/no), repeat biopsy 
(yes/no), DRE-positive finding (yes/no) and type of anti-
microbial prophylaxis (FT/CIP). Statistical significance 
was set at p < 0.05. All reported p values are two sided. All 
statistical analyses were performed by using SPSS 11.0 for 
Apple Macintosh (SPSS Inc., Chicago, Illinois).
Results
In total, 1109 patients who had undergone TR-PB were 
included in this retrospective study, of which 632 received 
FT (Group 1) and 477 CIP (Group 2) for prophylaxis, 
respectively. No clinically significant infectious complica-
tions were found among patients excluded from the analy-
sis [(Group 1: 73, Group 2: 189 (Fig. 1)] due to data lack-
ing. All patients’ clinical and laboratory characteristics at 
the time of the procedure are summarized in Table 1. The 
two groups did not differ significantly in terms of clinical 
or other procedure-related parameters.
Non‑infectious prostate biopsy complications
The most common recorded non-infectious complication 
was macrohematuria that was found in 442 patients in Group 
1 (69.9 %) and in 338 in Group 2 (70.8 %), without any sta-
tistically significant difference (p = 0.78). All reported non-
infectious complications are displayed in Table 2.
Symptomatic UTIs after biopsy
Seventy-two patients showed symptomatic UTIs (6.5 %): 
10 out of 632 patients in Group 1 (1.6 %) and 62 out of 477 
in Group 2 (12.9 %) (p < 0.001).
Group 1 (fosfomycin trometamol)
In Group 1, we found 5 cases with afebrile UTIs (0.8 %) 
and 3 cases with febrile UTIs (0.5 %) not requiring hos-
pitalization. These patients were treated with antibiotics in 
line with susceptibility testing. Furthermore, we found 2 
cases of urosepsis (0.3 %) that required hospitalization and 
parenteral antibiotic therapy.
Group 2 (ciprofloxacin)
In Group 2, we found 25 cases with afebrile UTIs (5.2 %) 
and 28 cases with febrile UTIs (5.9 %) not requiring hos-
pitalization. These patients were treated in line with sus-
ceptibility testing. Furthermore, 9 cases of urosepsis were 
registered (1.8 %).
The two groups were statistically significantly dif-
ferent in terms of symptomatic UTIs (1.6 vs 12.9 %; 
World J Urol 
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p < 0.001) and urosepsis (0.3 vs 1.8 %; p = 0.02). The 
most common isolated strains from patients with sympto-
matic UTIs were as follows: E. coli, Enterococcus faeca-
lis and Klebsiella spp. Fifty-three (73.6 %) symptomatic 
UTIs were caused by fluoroquinolone-resistant strains. 
All clinical symptoms and microbiological findings in 
patients with symptomatic UTIs are displayed in detail 
in Table 3.
Table 1  Patient clinical and 
laboratory characteristics at the 
time of the prostate biopsy
Data in parentheses are percentages unless otherwise specified
SD Standard deviation, UTIs urinary tract infection
a UTIs: yes/no due to fluoroquinolone-resistant strains
p (t or χ2/df)
Group 1 (Fosfomycin trometamol) 2 (Ciprofloxacin)
No. of patients 632 477
Median age (±SD) 65.9 (±8.3) 66.9 (±8.9) 0.05 (1.92/1107)
Previous UTIsa 0.59 (0.28/1)
 Yes 32 (5.0) 20 (4.1)
 No 600 (95.0) 457 (95.9)
Charlson comorbidity index 0.14 (2.14/1)
 0 598 (94.6) 461 (96.6)
 1 32 (5.0) 16 (3.4)
 2 2 (0.4) –
Rate of diabetes mellitus 62 (9.8) 40 (8.3) 0.47 (0.50/1)
Smoking 0.74 (0.11/1)
 Yes 284 (44.9) 220 (46.1)
Body mass index (Kg/m2) (±SD) 25.2 (±2.61) 24.8 (±2.91) 0.07 (1.80/1107)
PSA total (±SD) 7.14 (±4.31) 7.69 (±5.09) 0.05 (1.94/1107)
DRE-positive finding 76 (12.02) 58 (12.1) 0.94 (0.005/1)
Repeat biopsy 90 (14.2) 63 (13.2) 0.68 (0.16/1)
IPSS (±SD) 7.9 (±6.1) 7.3 (±5.9) 0.10 (1.64/1107)
IIEF-15 (±SD) 17.9 (±3.5) 18.1 (±2.9) 0.31 (1.01/1107)
Table 2  Clinical, histological 
data and non-infectious 
complication after prostate 
biopsy
Data in parentheses are percentages unless otherwise specified
a BPH, Benign Prostatic Hyperplasia
b Acute urinary retention: this complication required indwelling catheter for 1 week
c Rectal bleeding: this complication required a transrectal absorbable hemostatic gelatin sponge
p (t or χ2/df)
Group 1 (Fosfomycin trometamol) 2 (Ciprofloxacin)
Histological findings 0.76 (0.08/1)
 Prostate cancer 285 (45.1) 210 (44.0)
 BPHa 332 (52.5) 251(52.6)
 Normal prostate tissue 15 (2.4) 16 (3.4)
Adverse events related to the antibiotics 4 (0.6) 2 (0.4) 0.94 (0.004/1)
Clavien–Dindo score
Grade 1 598 (94.6) 438 (91.8) 0.08 (3.01/1)
 Macrohematuria 442 (73.9) 338 (77.1)
 Hematospermia 34 (5.7) 22 (5.1)
 Macrohematuria and Hematospermia 60 (10.1) 41 (9.4)
 Dysuria 62 (10.3) 37 (8.4)
Grade 2 58 (9.1) 41 (8.5) 0.81 (0.05/1)
 Acute urinary retentionb 41 (70.6) 36 (87.8)
 Rectal bleedingc 17 (29.4) 5 (12.2)
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Multivariate analysis
The Charlson comorbidity index (≤1) and type of antimi-
crobial prophylaxis (FT) were found to be associated with 
a lower probability of symptomatic UTIs development in 
the multivariate model [(Charlson comorbidity index (≤1) 
p = 0.01 HR 3.49; 95 % 1.67–3.11; type of antimicro-
bial prophylaxis (FT) p = 0.01 HR 2.67; 95 % 1.34–3.96) 
(Table 4).
Adverse drug reactions
In Group 1, we found 4 mild adverse events (0.6 %) that 
did not require any additional treatment: 3 cases with 
diarrhea and 1 drug-related hives (treated with medical 
therapy). Also, in Group 2 we found a low prevalence 
of adverse events: 2 cases with diarrhea (0.4 %). No sta-
tistically significant difference between the two groups 
was observed in terms of adverse events (0.6 vs 0.4 %; 
p = 0.94).
Discussion
Main findings
Fluoroquinolones are recommended as the first choice for 
antibiotic prophylaxis in TR-PB by EAU [18] and AUA 
[25] guidelines, but in the last few years, the increas-
ing resistance to fluoroquinolones has caused an alarm-
ing increase in severe infectious complications after pros-
tate biopsy [26]. Recently, Wagenlehner et al. [3] reported 
that fluoroquinolones were used in 98.2 % of patients, but 
resistance against fluoroquinolones was seen in 60 % of 
all bacterial strains isolated after the procedure. An alter-
native strategy to the fluoroquinolone-based prophylaxis 
is therefore needed [9, 27]. Here, we performed a retro-
spective cohort analysis in patients who underwent TR-PB 
and demonstrated that FT may be an attractive alternative 
antimicrobial prophylaxis for TR-PB due to a lower rate 
of symptomatic UTIs and a lower rate of adverse events as 
compared with CIP.
Table 3  Symptomatic 
UTI complications and 
microbiological findings after 
prostate biopsy
Data in parentheses are percentages unless otherwise specified
p (t or χ2/df)
Patients with symptomatic UTIs 72 (6.4)
Group 1 (Fosfomycin trometamol) 2 (Ciprofloxacin)
Symptomatic UTIs 10 (1.6) 62 (12.9) <0.001 (56.48/1)
 Afebrile UTIs 5 25
 Febrile UTIs 5 37
Positive urine culture 10 (100) 58 (93.5) 0.68 (0.16/1)
Positive blood culture 3 (30) 24 (38.7) 0.13 (2.28/1)
Urosepsis (among all febrile UTIs) 2 (0.3) 9 (1.8) 0.02 (5.32/1)
Isolated bacteria strains 0.66 (0.19/1)
 Escherichia coli 8 (80) 39 (67.2)
  Fluoroquinolone-resistant E. coli 6 15
  ESBL E. coli 3 9
 Enterococcus faecalis 1 (10) 11 (18.9)
 Klebsiella spp. 1 (10) 8 (13.9)
Table 4  Univariate and multivariate analysis results of factors affecting of symptomatic UTIs development risk in all enrolled patients
CI Confident interval, DRE digital rectal examination
Categories (variables) Univariate analysis (p) (HR; 95 % CI) Multivariate analysis (p) (HR; 95 % CI)
Previous UTIs (yes/no) (0.66) (HR 0.61; 0.14–1.25) (0.38)(HR 0.82; 0.65–1.01)
Charlson comorbidity index (0/1/2) (0.03) (HR 2.92; 0.97–3.98) (<0.01) (HR 3.49; 1.67–3.11)
Smoking (yes/no) (0.82) (HR 0.52; 0.10–1.46) (0.66) (HR 0.21; 0.08–1.17)
Repeat biopsy (yes/no) (0.09) (HR 1.01; 0.22–1.54) (0.10) (HR 1.25; 0.75–1.89)
DRE-positive finding (yes/no) (0.70) (HR 0.32; 0.45–1.67) (0.69) (HR 051; 0.20–1.14)
Type of antimicrobial prophylaxis (FT/CIP) (0.04) (HR 2.43; 1.42–3.21) (<0.01) (HR 2.67; 1.34–3.96)
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Comparisons with other studies
Ongün et al. [15] evaluated the efficacy of single-dose FT 
prophylaxis in comparison with fluoroquinolone-based 
prophylaxis in patients undergone TR-PB. They found that 
among all patients with febrile UTI, 5.2 % received proph-
ylaxis with FT while 94.8 % received fluoroquinolone-
based prophylaxis [15]. In other words, FT seems to be 
an effective drug and a valid alternative for antimicrobial 
prophylaxis in TR-PB [15]. In 1998, Periti et al. [28] found, 
in a large cohort of patients undergoing transurethral resec-
tion of the prostate (TURP), that the incidence of signifi-
cant postoperative bacteriuria in patients who received FT 
as prophylaxis was significantly lower than in the amoxicil-
lin and cotrimoxazole groups. Recently, Rhodes et al. [27] 
determined the optimal administration time for peri-proce-
dural prophylaxis with FT in an in vivo model. The authors 
evaluated the concentrations of FT in plasma, peripheral 
zone and transition zone of the prostate in 26 subjects 
undergoing TURP, following a single oral dose of 3 g of FT 
[27]. They recommended that for prophylaxis, FT should 
be given 1–4 h prior to prostate biopsy [27]. Moreover, they 
demonstrated that the concentrations of FT in the transi-
tional zone of the prostate exceeded 4 mg/L for 90 % of the 
population between 1 and 9 h after administration [27]. The 
concentrations of FT in the peripheral zone of the pros-
tate were much lower and exceeded only 4 mg/L in 70 % 
of the population between 1 and 4 h after administration 
[27]. In our study, we administered 3 g of FT 3 h before the 
procedure, in line with the findings in the Rhodes’s study 
[27]; moreover, in accordance with the national registra-
tion recommendations we also gave a second dose after 
the procedure. Recently, Lista et al. [29] demonstrated, in 
a randomized prospective study on 671 patients who had 
undergone TR-PB, that antibiotic prophylaxis with FT (2 
doses of 3 g) is a good alternative in terms of efficacy and 
safety when compared with a long-term therapy with CIP 
(10 doses of 500 mg). Moreover, the use of FT is correlated 
with lower rate of resistance [29]. In the Lista’s study, the 
urine culture was carried out at 2 weeks after biopsy [29], 
while in our study we collected a urine culture at 30 days 
from the procedure. We consider it advantageous to test the 
urine culture at 30 days for obtaining a longer microbio-
logical follow-up period.
Strengths and limitations of the present study
Since the rate of severe febrile UTIs after prostate biopsy is 
still rather low, it is important to enroll a sufficiently high 
number of patients to demonstrate statistically significant 
differences as shown in our study. As controls, we selected 
only patients with CIP prophylaxis in order for the group to 
be as homogenous as possible for comparison. All patients 
underwent a standardized prostate biopsy procedure, which 
can be considered another strength of this study. Limita-
tions of the study are the retrospective nature and the lack 
of a centralized microbiological laboratory. However, all 
laboratories involved in this study followed the same pro-
cedure of bacterial identification and the same EUCAST 
guidelines for antibiotic sensibility evaluation. We there-
fore consider the limitations of our study to be of minor 
importance for the outcome.
Clinical implications
Losing fluoroquinolones as first-choice antibiotics for 
prophylaxis in prostate biopsies may have significant impli-
cations, not only because diagnosis and treatment of pros-
tate cancer depends on prostate biopsy as a safe procedure, 
but also because no other oral antibiotics can replace fluo-
roquinolones, except FT. Besides resistance to fluoroqui-
nolones, Gram-negative uropathogens often show parallel 
resistance to trimethoprim/sulfamethoxazole and betalac-
tams, including third generation cephalosporins and broad-
spectrum penicillins, even if combined with betalactamase 
inhibitors (BLI), such as amoxicillin/clavulanic acid [27]. 
Thus, alternatives to CIP easily involve intravenous broad-
spectrum antibiotics, which are not recommended for 
prophylaxis according to the EAU guidelines. Prolonged 
antibiotic prophylaxis extending beyond 24 h is also not 
in line with the EAU guidelines. The 5-day course of CIP 
as was given in our study might have been of benefit for 
some individual patients but might cause collateral damage 
to others and should be avoided according to the principles 
of antibiotic stewardship [17, 30]. Therefore, a prospective, 
randomized study with a peri-procedural one-day dosing of 
FT as used in the present retrospective study, as compared 
to a single dose of CIP would be highly recommended. The 
increasing number of men with prostate cancer on active 
surveillance is correlated with a higher rate of repeat biop-
sies that have a higher risk of infectious complications than 
primary biopsies [30]. Moreover, the finding that fluoro-
quinolone resistant and extended-spectrum betalactamases 
(ESBL)-producing isolates were the most commonly iden-
tified organisms in their cohort of patients highlights the 
need for appropriate information of surveillance patients 
about the increased risks associated with repeat prostate 
biopsies and the need for a thoughtful and tailored antibi-
otic prophylaxis [30].
Conclusions
In conclusion, FT appeared to be an attractive alternative 
antibiotic for peri-interventional prophylaxis in patients 
undergoing TR-PB due to a low rate of ADRs and a low 
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rate of bacterial resistance against FT without cross- or par-
allel-resistance to other frequently used antibiotics.
Acknowledgments We are grateful to all members of the microbio-
logical departments in all centers for their assistance and to Professor 
John Denton for manuscript language revision.
Authors’ contribution Cai T. and Gallelli L. contributed to study 
conception and design; Cocci A., Tiscione D., Verze P., Lanciotti M., 
Vanacore D., Rizzo M., Gacci M., Saleh O., Damiano R., Palmieri A., 
Malossini G. and Liguori G helped in the acquisition of data; Cai T., 
Verze P. and Tiscione D. analyzed and interpreted the data; Cai T. and 
Gallelli L. drafted the manuscript; Wagenlehner F., Naber K., Mirone 
V. and Bjerklund Johansen T.E.is acknowledged for critical revision 
and supervisions; and Bjerklund Johansen T.E., Naber K., Bartoletti 
R., Mirone V., Carini M. and Trombetta C. supervised the intellectual 
concept.
Compliance with ethical standards 
Conflict of interest Tommaso Cai has received grant from Zambon as 
speaker at scientific meeting; Kurt Naber and Florian Wagenlehner are 
consultant for and have received research support and grant as speak-
ers at scientific meeting from Zambon.
References
 1. Chun FK, Epstein JI, Ficarra V et al (2010) Optimizing perfor-
mance and interpretation of prostate biopsy: a critical analysis of 
the literature. Eur Urol 58:851–864
 2. Wagenlehner FM, van Oostrum E, Tenke P et al (2013) Infective 
complications after prostate biopsy: outcome of the Global Prev-
alence Study of Infections in Urology (GPIU) 2010 and 2011, a 
prospective multinational multicentre prostate biopsy study. Eur 
Urol 63(3):521–527
 3. Cai T, Verze P, Bartoletti R et al (2015) Infectious complications 
after prostate biopsy: Time to rethink our clinical practice. World 
J Clin Urol 4(2):78–82
 4. Zani EL, Clark OA, Rodrigues Netto N Jr (2011) Antibiotic 
prophylaxis for transrectal prostate biopsy. Cochrane Database 
Syst Rev 5:CD006576
 5. Nam RK, Saskin R, Lee Y et al (2010) Increasing hospital 
admission rates for urological complications after transrectal 
ultrasound guided prostate biopsy. J Urol 183:963–968
 6. Carignan A, Roussy JF, Lapointe V et al (2012) Increasing risk 
of infectious complications after transrectal ultrasound-guided 
prostate biopsies: time to reassess antimicrobial prophylaxis? 
Eur Urol 62(3):453–459
 7. Bartoletti R, Cai T (2013) Prostate biopsies should be performed 
according to a standard of care. Eur Urol 63:528–529
 8. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos 
DE (2010) Fosfomycin for the treatment of multidrug-resistant, 
including extended-spectrum beta-lactamase producing, Entero-
bacteriaceae infections: a systematic review. Lancet Infect Dis 
10:43–50
 9. Wagenlehner FM, Thomas PM, Naber KG (2014) Fosfomycin 
trometamol (3000 mg) in perioperative antibiotic prophylaxis of 
healthcare-associated infections after endourological interven-
tions: a narrative review. Urol Int 92(2):125–130
 10. Rhodes NJ, Gardiner BJ, Neely MN et al (2015) Optimal timing 
of oral fosfomycin administration for pre-prostate biopsy proph-
ylaxis. J Antimicrob Chemother 70(7):2068–2073
 11. Clavien PA, Barkun J, de Oliveira ML et al (2009) The Clavien–
Dindo classification of surgical complications: five-year experi-
ence. Ann Surg 250:187–196
 12. Definition of historic cohort study—NCI Dictionary of Can-
cer Terms. http://www.cancer.gov/publications/dictionaries/
cancer-terms?CdrID=286525
 13. European Association of Urology Guidelines on Prostate Cancer, 
update 2014. http://uroweb.org/wp-content/uploads/1607-Pros-
tate-Cancer_LRV3.pdf
 14. Testa G, Cacciatore F, Galizia G et al (2009) Charlson Comor-
bidity Index does not predict long-term mortality in elderly sub-
jects with chronic heart failure. Age Ageing 38(6):734–740
 15. Ongün S, Aslan G, Avkan-Oguz V (2012) The effectiveness of 
single-dose fosfomycin as antimicrobial prophylaxis for patients 
undergoing transrectal ultrasound-guided biopsy of the prostate. 
Urol Int 89(4):439–444
 16. Horan TC, Gaynes RP (2004) Surveillance of nosocomial infec-
tions. In: Mayhall CG (ed) Hospital epidemiology and infection 
control, 3rd edn. Lippincott, Williams and Wilkins, pp 1659–1702
 17. Zaytoun OM, Vargo EH, Rajan R et al (2011) Emergence of 
fluoroquinolone-resistant Escherichia coli as cause of postpros-
tate biopsy infection: implications for prophylaxis and treatment. 
Urology 77:1035–1042
 18. European Association of Urology Guidelines on Urological 
Infections. 2014. http://uroweb.org/wp-content/uploads/19-Uro-
logical-infections_LR2.pdf
 19. Hooton TM, Scholes D, Gupta K et al (2005) Amoxicillin-clavu-
lanate vs ciprofloxacin for the treatment of uncomplicated cysti-
tis in women: a randomized trial. JAMA 293:949–955
 20. http://www.eucast.org/clinical_breakpoints/
 21. Badia X, Garcia-Losa M, Dal-Re R (1997) Ten-language trans-
lation and harmonization of the International Prostate Symptom 
Score: developing a methodology for multinational clinical tri-
als. Eur Urol 31(2):129–140
 22. Rosen RC, Riley A, Wagner G et al (1997) The international 
index of erectile function (IIEF): a multidimensional scale for 
assessment of erectile dysfunction. Urology 49(6):822–830
 23. Gallelli L, Ferreri G, Colosimo M et al (2002) Adverse drug 
reactions to antibiotics observed in two pulmonology divisions 
of Catanzaro, Italy: a six-year retrospective study. Pharmacol 
Res 46(5):395–400
 24. Naranjo CA, Busto U, Sellers EM et al (1981) A method for esti-
mating the probability of adverse drug reactions. Clin Pharmacol 
Ther 30(2):239–245
 25. Wolf JS Jr, Bennett CJ, Dmochowski RR et al (2008) Best prac-
tice policy statement on urologic surgery antimicrobial prophy-
laxis. J Urol 179:1379e90
 26. Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM (2011) 
Complications after prostate biopsy: data from SEER-Medicare. 
J Urol 186:1830e4
 27. Rhodes NJ, Gardiner BJ, Neely MN et al (2015) Optimal timing 
of oral fosfomycin administration for pre-prostate biopsy proph-
ylaxis. J Antimicrob Chemother 70(7):2068–2073
 28. Periti P, Novelli A, Reali EF, Lamanna S, Fontana P et al (1987) 
Prophylactic chemotherapy with fosfomycin trometamol salt 
during transurethral prostatic surgery: a controlled multicentre 
clinical trial. Eur Urol 13(suppl 1):122–131
 29. Lista F, Redondo C, Meilán E et al (2014) Efficacy and safety of 
fosfomycin-trometamol in the prophylaxis for transrectal pros-
tate biopsy. Prospective randomized comparison with ciprofloxa-
cin. Actas Urol Esp 38(6):391–396
 30. Tandogdu Z, Cek M, Wagenlehner F et al (2014) Resistance pat-
terns of nosocomial urinary tract infections in urology depart-
ments: 8-year results of the global prevalence of infections in 
urology study. World J Urol 32(3):791–801
View publication stats
